SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Recursion hosts an all-hands meeting at the biotech's Salt Lake City headquarters on April 15, featuring patient advocate Jenny Jones and her father Tim Jones.
Rare diseases
Patient advocate offers Recursion a powerful reason to keep going in rare disease
Staff at Salt Lake City-based techbio company Recursion recently heard from Jenny and Tim Jones about their challenging family history of familial adenomatous polyposis.
April 29, 2026
 · 
4 min read
 · 
Annalee Armstrong
Bird: Lesser Kestrel.
Mergers & acquisitions
AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B
AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for the oral pan-KRAS inhibitor KST-6051 in solid tumors.
April 28, 2026
 · 
1 min read
 · 
Annalee Armstrong
Strategy for company development concept. Employees conduct comparative analysis to improve their work. Competitiveness of business. Cartoon flat vector illustration isolated on blue background
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
 · 
2 min read
 · 
Heather McKenzie
Panoramic view of San Diego skyline with clear blue sky and calm ocean waters.
Cancer
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer
Cancer cocktails pairing Moderna’s mRNA-4359 with Merck’s Keytruda and Marengo’s invikafusp alfa with Gilead Sciences’ Trodelvy showed promising results, while a complex combination by Agenus and MiNK Therapeutics failed to elicit an overall response.
April 28, 2026
 · 
5 min read
 · 
Andrea Park
The path to precision. The road to the center of the target. The concept of goal achievement, precision, strategic direction, and focus on results. Polygonal design, blue background.
Deals
Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’
Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.
April 28, 2026
 · 
2 min read
 · 
Gabrielle Masson
Crossed fingers and polygraph. Dishonesy, fake news, manipulation concept. Vector illustration.
Regulatory
FDA alleges ‘manipulated’ data supported approval of Amgen’s autoimmune drug
The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study personnel doctored the results of the drug’s pivotal study in order to make it look effective.
April 28, 2026
 · 
2 min read
 · 
Tristan Manalac
Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.
Earnings
Novartis’ sales dip as generics pressure intensifies, radioequivalents loom
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
April 28, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessman receiving large stacks of money from a giant hand. Concept of funding, venture capital, financial support, dividend, and profitable business.
Venture capital
Big Pharma–backed Coultreon bags $125M series A to unlock alternative immune pathway
Coultreon Biopharma is advancing assets that target salt-inducible kinases, proteins that drive inflammation and other immune-mediated conditions.
April 28, 2026
 · 
2 min read
 · 
Tristan Manalac
man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top
Pancreatic cancer
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent protections and that the rival has “improperly compared” the companies’ assets publicly.
April 28, 2026
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS